Fibrogen, Inc. v. Akebia Therapeutics, Inc.

136 S. Ct. 1, 192 L. Ed. 2d 994, 84 U.S.L.W. 3099, 2015 U.S. LEXIS 4658, 2015 WL 5097135
CourtSupreme Court of the United States
DecidedAugust 31, 2015
DocketNo. 15A252.
StatusPublished

This text of 136 S. Ct. 1 (Fibrogen, Inc. v. Akebia Therapeutics, Inc.) is published on Counsel Stack Legal Research, covering Supreme Court of the United States primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Fibrogen, Inc. v. Akebia Therapeutics, Inc., 136 S. Ct. 1, 192 L. Ed. 2d 994, 84 U.S.L.W. 3099, 2015 U.S. LEXIS 4658, 2015 WL 5097135 (U.S. 2015).

Opinion

ANTHONY M. KENNEDY, Associate Justice of the Supreme Court of the United States.

UPON CONSIDERATION of the application of counsel for the applicant,

IT IS ORDERED that the order of the United States District Court for the Northern District of California granting discovery is stayed pending further order of the undersigned or of the Court.

Free access — add to your briefcase to read the full text and ask questions with AI

Cite This Page — Counsel Stack

Bluebook (online)
136 S. Ct. 1, 192 L. Ed. 2d 994, 84 U.S.L.W. 3099, 2015 U.S. LEXIS 4658, 2015 WL 5097135, Counsel Stack Legal Research, https://law.counselstack.com/opinion/fibrogen-inc-v-akebia-therapeutics-inc-scotus-2015.